Attributes | Values |
---|
rdf:type
| |
Description
| - Background An unmet medical need exists for patients with metastatic renal cell carcinoma who have progressed on VEGF-targeted and mTOR-inhibitor therapies. Fibroblast growth factor (FGF) pathway activation has been proposed as a mechanism of escape from VEGF-targeted therapies. Dovitinib is an oral tyrosine-kinase inhibitor that inhibits VEGF and FGF receptors. We therefore compared dovitinib with sorafenib as third-line targeted therapies in patients with metastatic renal cell carcinoma.
- Background An unmet medical need exists for patients with metastatic renal cell carcinoma who have progressed on VEGF-targeted and mTOR-inhibitor therapies. Fibroblast growth factor (FGF) pathway activation has been proposed as a mechanism of escape from VEGF-targeted therapies. Dovitinib is an oral tyrosine-kinase inhibitor that inhibits VEGF and FGF receptors. We therefore compared dovitinib with sorafenib as third-line targeted therapies in patients with metastatic renal cell carcinoma. (en)
|
Title
| - Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial
- Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial (en)
|
skos:prefLabel
| - Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial
- Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial (en)
|
skos:notation
| - RIV/61989592:15110/14:33148913!RIV15-MSM-15110___
|
http://linked.open...avai/riv/aktivita
| |
http://linked.open...avai/riv/aktivity
| |
http://linked.open...iv/cisloPeriodika
| |
http://linked.open...vai/riv/dodaniDat
| |
http://linked.open...aciTvurceVysledku
| |
http://linked.open.../riv/druhVysledku
| |
http://linked.open...iv/duvernostUdaju
| |
http://linked.open...titaPredkladatele
| |
http://linked.open...dnocenehoVysledku
| |
http://linked.open...ai/riv/idVysledku
| - RIV/61989592:15110/14:33148913
|
http://linked.open...riv/jazykVysledku
| |
http://linked.open.../riv/klicovaSlova
| - selection; evorolimus; expression; angiogenesis; VEGF; cancer; sunitinib; kinase inhibitor; serum-levels; fibroblast-growth-factor (en)
|
http://linked.open.../riv/klicoveSlovo
| |
http://linked.open...odStatuVydavatele
| - US - Spojené státy americké
|
http://linked.open...ontrolniKodProRIV
| |
http://linked.open...i/riv/nazevZdroje
| |
http://linked.open...in/vavai/riv/obor
| |
http://linked.open...ichTvurcuVysledku
| |
http://linked.open...cetTvurcuVysledku
| |
http://linked.open...UplatneniVysledku
| |
http://linked.open...v/svazekPeriodika
| |
http://linked.open...iv/tvurceVysledku
| - Melichar, Bohuslav
- Escudier, Bernard
- Porta, Camillo
- Bjarnason, Georg
- Cai, Can
- Davis, Lan D
- De Giorgi, Ugo
- Esteban, Emilio
- Gruenwald, Viktor
- Kollmannsberger, Christian
- Lee, Jae-Lyun
- Marker, Mahtab
- Motzer, Robert
- Rha, Sun Young
- Shi, Michael M
- Squires, Matthew
- Sternberg, Cora
- Szczylik, Cezaty
- Urbanowitz, Gladys
- Vogelzang, Nicholas
- Zolnierek, Jakub
|
issn
| |
number of pages
| |
http://bibframe.org/vocab/doi
| - 10.1016/S1470-2045(14)70030-0
|
http://localhost/t...ganizacniJednotka
| |